Welcome to our dedicated page for Centessa Pharmaceuticals Plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Centessa Pharmaceuticals plc filings document the regulatory record of a clinical-stage pharmaceutical issuer with American Depositary Shares listed on Nasdaq, each representing one ordinary share. Disclosures cover its orexin receptor 2 (OX2R) agonist focus, operating and financial results, corporate presentations, risk and capital-structure matters, and securities registered in connection with the ADS program.
Centessa's SEC filings also include Form 8-K material-event reports for underwriting and at-the-market sales agreements, public offerings of ADSs, executive and board changes, employment and advisory arrangements, and Regulation FD materials. Proxy filings describe governance, shareholder voting matters, compensation topics, and related public-company controls.
Centessa Pharmaceuticals plc filed an amendment detailing the employment agreement for its incoming Chief Executive Officer, Dr. Mario Alberto Accardi, effective January 1, 2026. Under the agreement, Dr. Accardi will receive a base salary of $600,000 and be eligible for a target annual bonus equal to 50% of his base salary. If the company terminates his employment without cause, or he resigns for good reason outside the one-year period following a sale event under the 2021 Stock Option and Incentive Plan, he will receive 12 months of salary continuation. If his employment is terminated without cause or he resigns for good reason within one year after a sale event, he will receive a lump sum equal to 18 months of base salary plus 150% of his target bonus for the year of termination. The agreement also includes provisions to adjust any payments that could be treated as parachute payments under Sections 280G and 4999 of the U.S. tax code.
Centessa Pharmaceuticals plc entered into an amended and restated sales agreement with Leerink Partners that allows it to issue and sell, from time to time, up to $250 million of American Depositary Shares in at-the-market offerings under an existing shelf registration statement. Leerink will act as sales agent and receive a commission of up to 3.0% of the gross proceeds from each sale, and the company will reimburse up to $150,000 of Leerink’s legal fees.
The company is not required to sell any shares and there is no minimum offering amount. The program will end when all placement shares are sold or the agreement is terminated. Centessa expects to use any net proceeds for working capital, capital expenditures and general corporate purposes.
Centessa Pharmaceuticals plc is registering an at-the-market offering of American Depositary Shares with an aggregate offering price of up to $250,000,000. The ADSs, each representing one ordinary share, will be sold from time to time through Leerink Partners LLC as sales agent on The Nasdaq Global Select Market under the symbol CNTA, with Leerink earning up to 3.0% of gross proceeds as commission. This is a primary offering, so Centessa will receive the net proceeds, which it plans to use, together with existing cash and investments, to fund development of its product candidates and for general corporate purposes. As context, Centessa had 134,421,149 ordinary shares outstanding as of September 30, 2025, and recently completed a separate underwritten offering that increased pro forma net tangible book value before giving effect to this ATM program.
Centessa Pharmaceuticals plc (CNTA) reported an insider transaction by its General Counsel on a Form 4. On 11/17/2025, the officer exercised a share option to buy 6,000 Ordinary Shares at $5.84 per share and, on the same day, sold 6,000 Ordinary Shares at a weighted average price of $27.6392 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 14, 2024. Following these transactions, the officer directly owns 105,386 Ordinary Shares and holds 221,559 share options beneficially. Each Ordinary Share may be represented by an American Depositary Share on the market.
Centessa Pharmaceuticals plc (CNTA) reported an insider equity transaction by its Chief Technology & Quality Officer. On 11/17/2025, the officer exercised a share option covering 40,000 Ordinary Shares at an exercise price of $9.42 per share and, on the same date, sold 40,000 Ordinary Shares at a price of $28 per share under a Rule 10b5-1 trading plan adopted on September 14, 2024. After these transactions, the officer directly owned 121,503 Ordinary Shares and held 360,338 derivative securities (share options) beneficially.
Centessa Pharmaceuticals (CNTA) entered an underwriting agreement to sell 11,627,907 American Depositary Shares (ADS) at $21.50 per ADS, with a 30‑day option for underwriters to purchase up to 1,744,186 additional ADS. The offering is being made under an automatic shelf registration on Form S‑3 and is expected to close on November 14, 2025, subject to customary conditions.
The company estimates net proceeds of approximately $234.4 million (or $269.6 million if the option is exercised in full). Centessa plans to use the proceeds, together with existing cash, cash equivalents, and short‑term investments, to fund continued development of its product candidates and for general corporate purposes. With the assumed net proceeds from the firm ADSs, management expects its cash resources to fund operations into 2028.
Centessa Pharmaceuticals plc launched a primary offering of 11,627,907 ADSs at $21.50 per ADS, for gross proceeds of $250,000,000. Underwriting discounts total $15,000,000 ($1.29/ADS), delivering proceeds before expenses of $235,000,000; estimated net proceeds are approximately $234.4 million.
The underwriters have a 30‑day option to purchase up to 1,744,186 additional ADSs. The company plans to use proceeds, together with existing cash, cash equivalents and investments, to fund continued development of product candidates and for general corporate purposes. Delivery is expected on or about November 14, 2025 (T+2).
Shares outstanding were 134,421,149 ordinary shares as of September 30, 2025. The offering results in immediate dilution of $17.84 per ADS to new investors, with an as‑adjusted net tangible book value of $3.66 per ADS after the offering. As of September 30, 2025, cash, cash equivalents and investments were $349.0 million, and following this offering the company expects funding into 2028. Company, executives and directors agreed to a 60‑day lock‑up; certain shareholders up to 10 trading days.
Centessa Pharmaceuticals (CNTA) launched a preliminary prospectus supplement for a primary offering of American Depositary Shares (ADSs) under its automatic shelf. The underwriters have a 30‑day option to purchase additional ADSs. ADSs trade on Nasdaq Global Select Market; the last reported sale price was $22.33 per ADS on November 10, 2025. Settlement is expected on a T+2 basis.
Centessa expects to use net proceeds, together with existing cash, for continued development of its product candidates and general corporate purposes. As of September 30, 2025, cash, cash equivalents and investments were $349.0 million, and the company expects funding runway into 2028. Ordinary shares outstanding were 134,421,149 as of September 30, 2025.
Recent R&D updates include ORX750 Phase 2a data across narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), with 55 participants completing dosing; ORX750 was generally well tolerated. In IH (2.0 mg, n=17), ORX750 improved mean sleep latency on the MWT (p=0.0213). ORX142 Phase 1 (89 volunteers) showed rapid onset, differentiated PK, and improvements on MWT, with patient studies planned.
The company, its executive officers and directors are subject to lock-up agreements (60 days), with certain shareholders subject to up to 10 trading days, subject to stated exceptions.
Centessa Pharmaceuticals (CNTA) reported Q3 2025 results. The company recorded a net loss of $54.9M for the quarter and $131.4M for the nine months. As of September 30, 2025, cash, cash equivalents and investments totaled $349.0M, and management stated this is expected to fund operations into mid-2027.
Operating expenses reflect continued pipeline investment: Q3 research and development was $41.6M and general and administrative was $12.2M. Year-to-date license and other revenue was $15.0M, primarily from an upfront payment under the Genmab LockBody license. Long-term debt stood at $110.0M principal (maturing in 2029). The company raised $6.1M in net proceeds via its ATM during the nine months. Shares outstanding were 134,447,836 ordinary shares as of October 31, 2025.
The SerpinPC program discontinuation charges recognized in 2024 were largely settled by Q3 2025, with the related contract termination liability effectively extinguished.
Centessa Pharmaceuticals (CNTA) furnished an update on its business, announcing financial results for the quarter ended September 30, 2025. The company attached a press release as Exhibit 99.1 and a corporate presentation as Exhibit 99.2, also posted on its investor website.
The materials are furnished, not filed, under the Exchange Act, which means they are not subject to Section 18 liability and are not incorporated by reference unless specifically stated.